Kommentarer og ledende artikler

Chren MM, Landefeld S, Murray TH. Doctors, drug companies, and gifts. JAMA 1989;262:3448-51.
Waud DR. Pharmaceutical promotions–a free lunch? N Engl J Med. 1992;327:351-3.
Shaughnessy AF, and Slawson DC. Pharmaceutical representatives (editorial). BMJ. 1996;312:1494.
Griffith D. Reasons for not seeing drug reps. BMJ. 1999; 319: 69-70.
Angell M The Pharmaceutical Industry: To Whom is it Accountable? NEJM. 2000;342:1902-1904.
Kassirer J. Financial Indigestion. JAMA. 2000;284:2156-7.
Wazana A and Primeau F. Ethical Considerations in the relationship between physicians and the pharmaceutical industry. Psychiatr Clin North Am. 2002 Sep;25(3):647-63.
Katz D, Caplan AL, Merz JF. All Gifts Large and Small. Am J Bioeth. 2003 Summer;3(3):39-46.
Dana J and Loewenstein GA. Social Science Perspective on Gifts to Physicians From Industry. JAMA. 2003;290:252-255.
Abbasi K and Smith R. No More Free Lunches. BMJ 2003;326:1155-1156.
Steinbrook R. Future directions in industry funding of continuing medical education. Arch Intern Med. 2011 Feb 14;171(3):257-8.
Kesselheim, A. S. and Orentlicher, D. INTRODUCTION: Insights from a National Conference: “Conflicts of Interest in the Practice of Medicine”. The Journal of Law, Medicine & Ethics 2012;40: 436–440.
Lo, B. The Future of Conflicts of Interest: A Call for Professional Standards. The Journal of Law, Medicine & Ethics 2012;40: 441–451.
Steinbrook, R. and Lo, B. Medical Journals and Conflicts of Interest. The Journal of Law, Medicine & Ethics 2012;40: 488–499.
Greenwood, K., Coleman, C. H. and Boozang, K. M. Toward Evidence-Based Conflicts of Interest Training for Physician-Investigators. The Journal of Law, Medicine & Ethics 2012;40: 500–510.
Rodwin, M. A. Conflicts of Interest, Institutional Corruption, and Pharma: An Agenda for Reform. The Journal of Law, Medicine & Ethics 2012;40: 511–522.
Clarke HD. Full disclosure is only the first step in managing potential conflicts of interest. J Bone Joint Surg Am. 2012 Jan 4;94(1):e5(1-2).